Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 4/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.33 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.31 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4255002 | 1.00 | CYP3A4 (0.43) | CYP3A4TDP1ESR1ESR2KCNA3 | |
| Hydrochloric Acid SCHEMBL15253811 | 0.97 | CYP3A4 (0.41) | CYP3A4TDP1ESR1ESR2 | |
| Hydrochloric Acid SCHEMBL1025430 | 0.97 | CYP3A4 (0.41) | CYP3A4TDP1ESR1ESR2 | |
| SCHEMBL35092 | 0.97 | CYP3A4 (0.45) | CYP3A4TDP1ESR1ESR2KCNA3 | |
| SCHEMBL954340 | 0.94 | CYP3A4 (0.43) | CYP3A4TDP1ESR1ESR2KCNA3 | |
| SCHEMBL7934432 | 0.94 | CYP3A4 (0.43) | CYP3A4TDP1ESR1ESR2KCNA3 | |
| SCHEMBL556980 | 0.94 | CYP3A4 (0.43) | CYP3A4TDP1ESR1ESR2KCNA3 | |
| SCHEMBL22749132 | 0.94 | CYP3A4 (0.43) | CYP3A4TDP1ESR1ESR2KCNA3 | |
| SCHEMBL22749145 | 0.94 | CYP3A4 (0.43) | CYP3A4TDP1ESR1ESR2KCNA3 | |
| SCHEMBL31379074 | 0.94 | CYP3A4 (0.43) | CYP3A4TDP1ESR1ESR2KCNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0653396-B1 | Process for the preparation of 1,1'-binaphthylene | HOECHST AG (DE) | 1997-02-12 | — | — | EP | claimed |
| US-5510554-A | REACTING A 1-HALO-2-SUBSTITUTED NAPHTHALENE WITH A 2-SUBSTITUTED-1-NAPHTHYL-MAGNESIUM HALIDE IN THE PRESENCE OF A PALLADIUM/PHOSPHINE CATALYST | HOECHST AKTIENGESELLSCHAFT (DE) | 1996-04-23 | — | — | US | claimed |
| EP-0653396-A1 | Process for the preparation of 1,1'-binaphthylene | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-05-17 | — | — | EP | claimed |
| US-8742127-B2 | Production method of 6-halogeno-3-arylpyridine derivative | KURARAY CO., LTD. (JP) | 2014-06-03 | — | — | US | disclosed |
| US-20100280253-A1 | PRODUCTION METHOD OF 6-HALOGENO-3-ARYLPYRIDINE DERIVATIVE | KURARAY CO., LTD. (JP) | 2010-11-04 | — | — | US | disclosed |
| EP-2223912-A1 | METHOD FOR PRODUCING 6-HALOGENO-3-ARYLPYRIDINE DERIVATIVE | Kuraray Co., Ltd. (JP) | 2010-09-01 | — | — | EP | disclosed |
| EP-0653396-B1 | Process for the preparation of 1,1'-binaphthylene | HOECHST AG (DE) | 1997-02-12 | — | — | EP | disclosed |
| EP-0743293-A1 | Process for producing biaryl compound | CHISSO CORPORATION (JP) | 1996-11-20 | — | — | EP | disclosed |
| US-5510554-A | REACTING A 1-HALO-2-SUBSTITUTED NAPHTHALENE WITH A 2-SUBSTITUTED-1-NAPHTHYL-MAGNESIUM HALIDE IN THE PRESENCE OF A PALLADIUM/PHOSPHINE CATALYST | HOECHST AKTIENGESELLSCHAFT (DE) | 1996-04-23 | — | — | US | disclosed |
| EP-0653396-A1 | Process for the preparation of 1,1'-binaphthylene | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-05-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280253-A1 | PRODUCTION METHOD OF 6-HALOGENO-3-ARYLPYRIDINE DERIVATIVE | GMDS, MAP2, DDT | CYP3A4 172/4885TDP1 1351/4885ESR1 4811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.